Specific adsorption of osteopontin and synthetic polypeptides to calcium oxalate monohydrate crystals

Biophysical Journal

Volumn 93, Issue 5, 2007, Pages 1768-1777

  Taller, Adam ^a   Grohe, Bernd ^a   Rogers, Kem A ^a   Goldberg, Harvey A ^a   Hunter, Graeme K ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM OXALATE; FLUORESCENT DYE; OSTEOPONTIN; POLYASPARTIC ACID; POLYGLUTAMIC ACID; POLYPEPTIDE;

ADSORPTION; ARTICLE; BIOMINERALIZATION; CONFOCAL MICROSCOPY; CRYSTAL; CRYSTAL STRUCTURE; FLUORESCENCE; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PROTEIN INTERACTION; RAT;

RATTUS;

EID: 34548656870     PISSN: 00063495     EISSN: None     Source Type: Journal    
DOI: 10.1529/biophysj.106.101881     Document Type: Article

References (45)

1. Lieske, J. C., and F. G. Toback. 2000. Renal cell-urinary crystal interactions. Curr. Opin. Nephrol. Hypertens. 9:349-355.
2. Shiraga, H., W. Min, W. J. VanDusen, M. D. Clayman, D. Miner, C. H. Terrell, J. R. Sherbotie, J. W. Foreman, C. Przysiecki, E. G. Nielson, and J. R. Hoyer. 1992. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc. Natl. Acad. Sci. USA. 89:426-430.
3. Worcester, E. M., S. S. Blumenthal, A. M. Beshensky, and D. L. Lewand. 1992. The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J. Bone Miner. Res. 7:1029-1036.
4. Wesson, J. A., E. M. Worcester, J. H. Wiessner, N. S. Mandel, and J. G. Kleinman. 1998. Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 53:952-957.
5. Wesson, J. A., V. Ganne, A. M. Beshensky, and J. G. Kleinman. 2005. Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers. Urol. Res. 33:206-212.
6. Hoyer, J. R. 1994. Uropontin in urinary calcium stone formation. Miner. Electrolyte Metab. 20:385-392.
7. Atmani, F., P. A. Glenton, and S. R. Khan. 1998. Identification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in the urine of healthy and stone forming subjects. Urol. Res. 26:201-207.
8. McKee, M. D., A. Nanci, and S. R. Khan. 1995. Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J. Bone Miner. Res. 10:1913-1929.
9. Kleinman, J. G., J. A. Wesson, and J. Hughes. 2004. Osteopontin and calcium stone disease. Nephron Physiol. 98:43-47.
10. Gokhale, J. A., P. A. Glenton, and S. R. Khan. 1996. Localization of Tamm-Horsfall protein and osteopontin in a rat nephrolithiasis model. Nephron. 73:456-461.
11. Yagisawa, T., P. S. Chandhoke, J. Fan, and S. Lucia. 1998. Renal osteopontin expression in experimental urolithiasis. J. Endourol. 12:171-176.
12. Kohri, K., S. Nomura, Y. Kitamura, T. Nagata, K. Yoshioka, M. Iguchi, T. Yamate, T. Umekawa, Y. Suzuki, H. Sinohara, and T. Kurita. 1993. Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J. Biol. Chem. 268:15180-15184.
13. Yasui, T., K. Fujita, S. Sasaki, M. Sato, M. Sugimoto, S. Hirota, Y. Kitamura, S. Nomura, and K. Kohri. 1999. Expression of bone matrix proteins in urolithiasis model rats. Urol. Res. 27:255-261.
14. Jiang, X. J., T. Feng, L. S. Chang, X. T. Kong, G. Wang, Z. W. Zhang, and Y. L. Guo. 1998. Expression of osteopontin mRNA in normal and stone-forming rat kidney. Urol. Res. 26:389-394.
15. Liaw, L., D. E. Birk, C. B. Ballas, J. S. Whitsitt, J. M. Davidson, and B. L. M. Hogan. 1998. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Invest. 101:1468-1478.
16. Rittling, S. R., H. N. Matsumoto, M. D. McKee, A. Nanci, X. R. An, K. E. Novick, A. J. Kowalski, M. Noda, and D. T. Denhardt. 1998. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J. Bone Miner. Res. 13:1101-1111.
17. Wesson, J. A., R. J. Johnson, M. Mazzali, A. M. Beshensky, S. Stietz, C. Giachelli, L. Liaw, C. E. Alpers, W. G. Couser, J. G. Kleinman, and J. Hughes. 2003. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J. Am. Soc. Nephrol. 14:139-147.
18. Mo, L., H. Y. Huang, X. H. Zhu, E. Shapiro, D. L. Hasty, and X. R. Wu. 2004. Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int. 66:1159-1166.
19. Sodek, J., B. Ganss, and M. D. McKee. 2000. Osteopontin. Crit. Rev. Oral Biol. Med. 11:279-303.
20. Sørensen, E. S., P. Højrup, and T. E. Petersen. 1995. Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci. 4:2040-2049.
21. Christensen, B., M. S. Nielsen, K. F. Haselmann, T. E. Petersen, and E. S. Sorensen. 2005. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem. J. 390:285-292.
22. Keykhosravani, M., A. Doherty-Kirby, C. Zhang, D. Brewer, H. A. Goldberg, G. K. Hunter, and G. Lajoie. 2005. Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry. Biochemistry. 44:6990-7003.
23. Fisher, L. W., D. A. Torchia, B. Fohr, M. F. Young, and N. S. Fedarko. 2001. Flexible structures of SIBLING proteins, bone sialoprotein and osteopontin. Biochem. Biophys. Res. Commun. 280:460-465.
24. Hoyer, J. R., J. R. Asplin, and L. Otvos. 2001. Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int. 60:77-82.
25. Boskey, A. L., M. Maresca, W. Ullrich, S. B. Doty, W. T. Butler, and C. W. Prince. 1993. Osteopontin-hydroxyapatite interactions in vitro. Inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 22:147-159.
26. Hunter, G. K., C. L. Kyle, and H. A. Goldberg. 1994. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem. J. 300:723-728.
27. Pampena, D. A., K. A. Robertson, O. Litvinova, G. Lajoie, H. A. Goldberg, and G. K. Hunter. 2004. Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem. J. 378:1083-1087.
28. Jono, S., C. Peinado, and C. M. Giachelli. 2000. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J. Biol. Chem. 275:20197-20203.
29. Hincke, M. T., and M. St. Maurice. 2000. Chapter 3. In Chemistry and Biology of Mineralized Tissues: Proceedings of the Sixth International Conference, Vittel, France, 1998. M. Goldberg, A. Boskey, and C. Robinson, editors. American Academy of Orthopaedic Surgeons, Rosemont, IL. 13-17.
30. Grohe, W., K. Rogers, H. A. Goldberg, and G. K. Hunter. 2006. Crystallization kinetics of calcium oxalate hydrates studied by scanning confocal interference microscopy. J. Cryst. Growth. 295:148-157.
31. Goldberg, H. A., and J. Sodek. 1994. Purification of mineralized tissue-associated osteopontin. J. Tissue Cult. Methods. 16:211-215.
32. Goldberg, H. A., K. J. Warner, M. C. Li, and G. K. Hunter. 2001. Binding of bone sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite. Connect. Tissue Res. 42:25-37.
33. Wesson, J. A., E. M. Worcester, and J. G. Kleinman. 2000. Role of anionic proteins in kidney stone formation: interaction between model anionic polypeptides and calcium oxalate crystals. J. Urol. 163:1343-1348.
34. Guo, S. W., M. D. Ward, and J. A. Wesson. 2002. Direct visualization of calcium oxalate monohydrate crystallization and dissolution with atomic force microscopy and the role of polymeric additives. Langmuir. 18:4284-4291.
35. Jung, T., X. Sheng, C. K. Choi, W. S. Kim, J. A. Wesson, and M. D. Ward. 2004. Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy. Langmuir. 20:8587-8596.
36. Shirane, Y., Y. Kurokawa, Y. Sumiyoshi, and S. Kagawa. 1995. Morphological effects of glycosaminoglycans on calcium oxalate monohydrate crystals. Scanning Microsc. 9:1081-1088 (discussion 1088).
37. Bader, C. A., A. Chevalier, C. Hennequin, P. Jungers, and M. Daudon. 1994. Methodological aspects of spontaneous crystalluria studies in calcium stone formers. Scanning Microsc. 8:215-232.
38. Morfin, J., and A. Chin. 2005. Images in clinical medicine. Urinary calcium oxalate crystals in ethylene glycol intoxication. N. Engl. J. Med. 353:e21.
39. Addadi, L., and S. Weiner. 1985. Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. Proc. Natl. Acad. Sci. USA. 82:4110-4114.
40. Wang, L., S. R. Qiu, W. Zachowicz, X. Guan, J. J. DeYoreo, G. H. Nancollas, and J. R. Hoyer. 2006. Modulation of calcium oxalate crystallization by linear aspartic acid-rich peptides. Langmuir. 22:7279-7285.
41. Touryan, L. A., R. H. Clark, R. W. Gurney, P. S. Stayton, B. Kahr, and V. Vogel. 2001. Incorporation of fluorescent molecules and proteins into calcium oxalate monohydrate single. J. Cryst. Growth. 233:380-388.
42. Qiu, S. R., A. Wierzbicki, C. A. Orme, A. M. Cody, J. R. Hoyer, G. H. Nancollas, S. Zepeda, and J. J. DeYoreo. 2004. Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc. Natl. Acad. Sci. USA. 101:1811-1815.
43. Sheng, X., T. Jung, J. A. Wesson, and M. D. Ward. 2005. Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc. Natl. Acad. Sci. USA. 102:267-272.
44. Millan, A. 2001. Crystal growth shape of whewellite polymorphs: influence of structure distortions on crystal shape. Cryst. Growth Des. 1:245-254.
45. Kurz, W., and D. J. Fisher. 1998. Fundamentals of Solidification. Trans Tech Publications, Zürich, Switzerland.